Ziopharm Oncology (ZIOP) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts ZIOP Hot Sheet
Price: $0.87 --0%
Financial Fact:
Loss from operations: -10.91M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Loss from operations: -10.91M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Ziopharm Oncology (NASDAQ: ZIOP) reported Q2 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $1.66 million.
For earnings history and earnings-related data on Ziopharm Oncology (ZIOP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- XPEL, Inc. (XPEL) Tops Q3 EPS by 4c, Misses on Revenue; Offers Q4 Revenue Guidance
- McDonald's posts better-than-expected third-quarter comparable sales
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
